When Lyria 3 launched last month, Gemini could generate 30-second audio clips from prompts. With the new advanced model, the chatbot can now create tracks up to 3 minutes long and follow instructions ...

We get it - academic writing can be tough. Between tight deadlines, endless assignments, and needing original ideas, creating great papers consistently isn't easy. We get it - academic writing can be ...

This paper presents the design and development of a comprehensive standalone application for geotechnical engineering, built entirely using Python. Unlike conventional commercial platforms or ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate Biomedicines Inc. shares slumped 21% in the company’s trading debut after it raised $400 million in an initial public offering. Shares of the Somerville, Massachusetts-based drug developer ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. At the IPO price, Generate would have a market value of about $2 ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

AI drug discovery specialist Generate Biomedicines has raised $400 million in the year’s largest initial public offering to date for a biotechnology firm. The company, which was launched in 2018 by ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Somerville company aims to ...